Description: Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.
Home Page: www.proventionbio.com
PRVB Technical Analysis
55 Broad Street
Red Bank,
NJ
07701
United States
Phone:
908 336 0360
Officers
| Name | Title |
|---|---|
| Mr. Ashleigh W. Palmer B.Sc., M.B.A. | Co-Founder, Pres, CEO & Director |
| Mr. Thierry Chauche | Chief Financial Officer |
| Dr. Eleanor L. Ramos M.D. | Chief Medical Officer |
| Dr. Francisco Leon M.D., Ph.D. | Co-Founder & Chief Scientific Officer |
| Ms. Christina Yi | Chief Operations Officer |
| Mr. Robert A. Doody Jr. | VP of Investor Relations |
| Ms. Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer |
| Kaelan Hollon | VP of Corp. Communications |
| Mr. Jason Levine | VP Marketing |
| Sarah O'Brien | Chief People Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.3121 |
| Price-to-Sales TTM: | 289.7011 |
| IPO Date: | 2018-07-24 |
| Fiscal Year End: | December |
| Full Time Employees: | 82 |